Evidence map›Paper›PMID 41602559›Full record

ArticleVaccine: X2025

High HBV Seroprotection Rates in Infants Born to People with HIV and HBV Infection in Sub-Saharan Africa.

Neaka Mohtashemi, Julia Spaczai, Rong Guo, Chi-Hong Tseng, Mary C Cambou, Lynda Emel, Hannah Ship, Tian-Hao Zhang, Shih-Hsin Chiu, Lynda Stranix-Chibanda and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Neaka MohtashemiDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA USA.
Julia SpaczaiDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA USA.
Rong GuoDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA USA.
Chi-Hong TsengDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA USA.
Mary C CambouDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA USA.
Lynda EmelFred Hutchinson Cancer Research Center, Seattle, WA USA.
Hannah ShipDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA USA.
Tian-Hao ZhangDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA USA.
Shih-Hsin ChiuDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA USA.
Lynda Stranix-ChibandaUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Tsungai ChipatoUniversity of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe.
Kenneth KintuMakerere University- Johns Hopkins University Research Collaboration, Kampala, Uganda.
Karim P ManjiMuhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Dhayendre MoodleyCentre for the AIDS Programme of Research in South Africa and Department of Obstetrics and Gynaecology, School of Clinical Medicine, University of KwaZulu Natal, Durban, South Africa.
Judith S CurrierDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA USA.
Chloe L ThioDepartment of Medicine, Johns Hopkins University, Baltimore, MD USA.
Yvonne MaldonadoStanford University, Stanford, CA USA.
Debika BhattacharyaDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA USA.

Funding

UZ-UCSF CTUUM1AI069436 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ZVAVAHERA MIKE CHIRENJE, LYNDA STRANIX-CHIBANDA · 2012 to 2026
$75.9M
UZ-UCSF Clinical Trials UnitU01AI069436 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHIRENJE, ZVAVAHERA MIKE · 2007 to 2011
$49.3M
University of KwaZulu-Natal - CAPRISA HIV/AIDS Clinical Trials UnitUM1AI069469 · NIAID · UNIVERSITY OF KWAZULU-NATAL · PI QUARRAISHA ABDOOL KARIM · 2012 to 2026
$36.4M
Lamivudine and its Impact on Perinatal HBV Transmission in HIV/HBV CoinfectionR01AI100748 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BHATTACHARYA, DEBIKA · 2012 to 2016
$1.9M
Impact of HIV PMTCT Interventions on HIV/HBV Co-infected Women and Their InfantsR01HD085862 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BHATTACHARYA, DEBIKA · 2016 to 2018
$1.3M
NIAID NIH HHS R01 AI100748NIAID NIH HHS U01 AI069436NIAID NIH HHS UM1 AI069436NIAID NIH HHS UM1 AI069469NICHD NIH HHS R01 HD085862
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Hepatitis BHIV/HBVinfant vaccinationvaccine seroprotection

Identifiers

PMID41602559
PMCPMC12834125

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.